|
1
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paulson AS, Tran Cao HS, Tempero MA and
Lowy AM: Therapeutic advances in pancreatic cancer.
Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo
N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment
during chemo- or radio-therapy for cancer. Biosci Trends.
4:297–307. 2010.
|
|
7
|
Normile D: Asian medicine. The new face of
traditional Chinese medicine. Science. 299:188–190. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li D: The anticancer drug Kang-Lai-Te
emulsion for infusion. Vestn Ross Akad Med Nauk. 9:32–37. 2005.In
Russian.
|
|
9
|
Liu X, Yang Q, Xi Y, Yu K, Wang W, Zhao X
and Kou X: Kanglaite injection combined with chemotherapy versus
chemotherapy alone in the treatment of advanced non-small cell lung
carcinoma. J Cancer Res Ther. 10(Suppl 1): S46–S51. 2014.
View Article : Google Scholar
|
|
10
|
Zhan YP, Huang XE, Cao J, Lu YY, Wu XY,
Liu J, Xu X, Xiang J and Ye LH: Clinical safety and efficacy of
Kanglaite® (Coix Seed Oil) injection combined with
chemotherapy in treating patients with gastric cancer. Asian Pac J
Cancer Prev. 13:5319–5321. 2012. View Article : Google Scholar
|
|
11
|
Fu F, Wan Y and Wu T: Mulati: Kanglaite
injection combined with hepatic arterial intervention for
unresectable hepatocellular carcinoma: A meta-analysis. J Cancer
Res Ther. 10(Suppl 1): S38–S41. 2014. View Article : Google Scholar
|
|
12
|
Tagliaferri MA, Schwartzberg LS, Chen MM,
Camacho LH, Kaplan EH, Arena FP, Bienvenu BJ, North SE, Patel H and
Li D: A phase IIb trial of coix seed injection for advanced
pancreatic cancer. J Clin Oncol. 31(Suppl): e150232013.
|
|
13
|
Sun Y, Li Y, Qin S, Ma D, Jiao SC, Yu SY,
Li J, Liu D, Song D and Li D: A multicenter randomized phase II
trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride
(GEM) versus GEM in patients with local advanced and metastatic
pancreatic cancer. J Clin Oncol. 29(Suppl): e145102011.
|
|
14
|
Jiang Y, Yuan Q, Huang A and Fang Q: The
synergistic mechanism of pemetrexed followed by Kanglaite was due
to KLT subsequently inhibiting the pemetrexed-activated MAPK
signaling pathway. Clin Lab. 61:1353–1363. 2015.PubMed/NCBI
|
|
15
|
Lu Y, Zhang BY, Jia ZX, Wu WJ and Lu ZQ:
Hepatocellular carcinoma HepG2 cell apoptosis and caspase-8 and
Bcl-2 expression induced by injectable seed extract of Coix
lacryma-jobi. Hepatobiliary Pancreat Dis Int. 10:303–307. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Woo JH, Li D, Wilsbach K, Orita H, Coulter
J, Tully E, Kwon TK, Xu S and Gabrielson E: Coix seed extract, a
commonly used treatment for cancer in China, inhibits NFkappaB and
protein kinase C signaling. Cancer Biol Ther. 6:2005–2011. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132.
2012.PubMed/NCBI
|
|
18
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
19
|
Arlt A, Gehrz A, Müerköster S, Vorndamm J,
Kruse ML, Fölsch UR and Schäfer H: Role of NF-kappaB and Akt/PI3K
in the resistance of pancreatic carcinoma cell lines against
gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qanungo S, Uys JD, Manevich Y, Distler AM,
Shaner B, Hill EG, Mieyal JJ, Lemasters JJ, Townsend DM and
Nieminen AL: N-acetyl-L-cysteine sensitizes pancreatic cancers to
gemcitabine by targeting the NFκB pathway. Biomed Pharmacother.
68:855–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Banerjee S, Kaseb AO, Wang Z, Kong D,
Mohammad M, Padhye S, Sarkar FH and Mohammad RM: Antitumor activity
of gemcitabine and oxaliplatin is augmented by thymoquinone in
pancreatic cancer. Cancer Res. 69:5575–5583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan P, Wu Y, Guo ZY, Wang R, Wang YJ and
Yuan YF: Antitumor activity and immunomodulatory effects of the
intraperitoneal administration of Kanglaite in vivo in Lewis lung
carcinoma. J Ethnopharmacol. 143:680–685. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gu M, Yu Y, Gunaherath GM, Gunatilaka AA,
Li D and Sun D: Structure-activity relationship (SAR) of
withanolides to inhibit Hsp90 for its activity in pancreatic cancer
cells. Invest New Drugs. 32:68–74. 2014. View Article : Google Scholar
|
|
24
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3′-Diindolylmethane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung CP, Hsu CY, Lin JH, Kuo YH, Chiang W
and Lin YL: Antiproliferative lactams and spiroenone from adlay
bran in human breast cancer cell lines. J Agric Food Chem.
59:1185–1194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arlt A, Vorndamm J, Müerköster S, Yu H,
Schmidt WE, Fölsch UR and Schäfer H: Autocrine production of
interleukin 1beta confers constitutive nuclear factor kappaB
activity and chemoresistance in pancreatic carcinoma cell lines.
Cancer Res. 62:910–916. 2002.PubMed/NCBI
|
|
28
|
Cao LP, Song JL, Yi XP and Li YX: Double
inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of
pancreatic cancer cells to gemcitabine. Oncol Rep. 29:1659–1665.
2013.PubMed/NCBI
|
|
29
|
Zhou L, Qi L, Jiang L, Zhou P, Ma J, Xu X
and Li P: Antitumor activity of gemcitabine can be potentiated in
pancreatic cancer through modulation of TLR4/NF-κB signaling by
6-shogaol. AAPS J. 16:246–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Ma J, Wu Z, Li W, Zhang D, Han L,
Wang F, Reindl KM, Wu E and Ma Q: Arginine deiminase augments the
chemosensitivity of argininosuccinate synthetase-deficient
pancreatic cancer cells to gemcitabine via inhibition of NF-κB
signaling. BMC Cancer. 14:6862014. View Article : Google Scholar
|
|
31
|
Maier HJ, Schmidt-Strassburger U, Huber
MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes
epithelial-mesenchymal transition, migration and invasion of
pancreatic carcinoma cells. Cancer Lett. 295:214–228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al European Study Group for Pancreatic Cancer: A
randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chiorean EG and Coveler AL: Pancreatic
cancer: Optimizing treatment options, new, and emerging targeted
therapies. Drug Des Devel Ther. 9:3529–3545. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carbone C and Melisi D: NF-κB as a target
for pancreatic cancer therapy. Expert Opin Ther Targets. 16(Suppl
2): S1–S10. 2012. View Article : Google Scholar
|
|
36
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and
overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33.
2011. View Article : Google Scholar
|
|
37
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luqman S and Pezzuto JM: NFkappaB: A
promising target for natural products in cancer chemoprevention.
Phytother Res. 24:949–963. 2010.PubMed/NCBI
|
|
39
|
Lu Y, Li CS and Dong Q: Chinese herb
related molecules of cancer-cell-apoptosis: A minireview of
progress between Kanglaite injection and related genes. J Exp Clin
Cancer Res. 27:312008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Y, Zhang W, Wang XJ and Liu S:
Antitumor effect of Kanglaite® injection in human
pancreatic cancer xenografts. BMC Complement Altern Med.
14:2282014. View Article : Google Scholar
|
|
41
|
Hill R, Li Y, Tran LM, Dry S, Calvopina
JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR, et al: Cell
intrinsic role of COX-2 in pancreatic cancer development. Mol
Cancer Ther. 11:2127–2137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang C, Tan T, Yi XP, Shen H and Li YX:
Lentivirus-mediated shRNA targeting XIAP and survivin inhibit
SW1990 pancreatic cancer cell proliferation in vitro and in vivo.
Mol Med Rep. 4:667–674. 2011.PubMed/NCBI
|
|
43
|
Dong J, Zhao YP, Zhou L, Zhang TP and Chen
G: Bcl-2 upregulation induced by miR-21 via a direct interaction is
associated with apoptosis and chemoresistance in MIA PaCa-2
pancreatic cancer cells. Arch Med Res. 42:8–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ali S, Banerjee S, Schaffert JM, El-Rayes
BF, Philip PA and Sarkar FH: Concurrent inhibition of NF-kappaB,
cyclooxygenase-2, and epidermal growth factor receptor leads to
greater anti-tumor activity in pancreatic cancer. J Cell Biochem.
110:171–181. 2010.PubMed/NCBI
|
|
45
|
Li L, Aggarwal BB, Shishodia S, Abbruzzese
J and Kurzrock R: Nuclear factor-kappaB and IkappaB kinase are
constitutively active in human pancreatic cells, and their
down-regulation by curcumin (diferuloylmethane) is associated with
the suppression of proliferation and the induction of apoptosis.
Cancer. 101:2351–2362. 2004. View Article : Google Scholar : PubMed/NCBI
|
